Abstract Body

An estimated 1.5 million HIV-positive women become pregnant each year, 90% of whom live in regions where breastfeeding is WHO-recommended infant feeding option. Changes to WHO and national policies in recent years mean that an increasing number of infants are exposed to ART throughout pregnancy and breastfeeding. The clear benefit to the infant is the huge reduction in risk of HIV acquisition, from around 40% in the pre-ART era, through to less than 1% in clinical trials, even among breastfeeding populations. Less clear are the potential risks to the infant of long-term low dose ART exposure through breast milk. Potential risks include the development of HIV-drug resistance in the infant should HIV infection occur, and toxicities due to drug exposure. This talk will summarise the existing pharmacokinetic data regarding ART transfer into breast milk and to the breastfed HIV-negative infant, will summarise existing data regarding potential risk of HIV-drug resistance in the infant should transmission occur and will review available data regarding drug toxicity in the infant. Finally, current and future priorities for research and monitoring will be presented.